Meeting
2017 ASCO Annual Meeting
Response rates with pembrolizumab in combination with rituximab in patients with relapsed follicular lymphoma: Interim results of an on open-label, phase II study.
Authors
Loretta J. Nastoupil
The University of Texas MD Anderson Cancer Center, Houston, TX
Loretta J. Nastoupil , Jason R. Westin , Nathan Hale Fowler , Michelle A. Fanale , Felipe Samaniego , Yasuhiro Oki , Chizobam Obi , JingJing Cao , Xiaoyun Cheng , Man Chun John Ma , Zhiqiang Wang , Fuliang Chu , Lei Feng , Shouhao Zhou , Richard Eric Davis , Sattva Swarup Neelapu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT02446457
Citation
J Clin Oncol 35, 2017 (suppl; abstr 7519)
DOI
10.1200/JCO.2017.35.15_suppl.7519
Abstract #
7519
Poster Bd #
281
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
KEYNOTE B68: Open-label phase 2 study of the efficacy and safety of pembrolizumab administered every six weeks in patients with relapsed or refractory classical Hodgkin lymphoma or primary mediastinal B-cell lymphoma.
First Author: Philippe Armand
Poster
2021 ASCO Annual Meeting
CMP-001-007: Open-label, phase 2 study of intratumoral CMP-001 + pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma.
First Author: Deborah J.L. Wong
Poster
2023 ASCO Annual Meeting
Phase II randomized trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC): Final results.
First Author: Andreas Nicholas Saltos
Poster
2023 ASCO Genitourinary Cancers Symposium
Digital evaluation of tumor microenvironment immune markers pre- and post-neoadjuvant pembrolizumab in muscle-invasive bladder cancer (Pure-01 trial: An open label, single arm, phase II study).
First Author: Laura Cattaneo